Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. with Avere Therapeutics, Inc. over concerns that NextCure shareholders may not be receiving a fair price. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately 1.21% of the combined company. The investigation focuses on whether NextCure and its board violated federal securities laws or breached fiduciary duties by failing to obtain the best possible price, conduct a fair sales process, or disclose all material information. Halper Sadeh may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
NextCure IncInvestigation over merger fairness and potential securities law violations creates legal risk and may reduce shareholder value.